Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™

Orthogonal Methods

Orthogonal Analytics: How Much Characterization Is Enough?

David Alvaro, Ph.D.

Pharma's Almanac

SmartScale

Phase-Appropriate CMC Requires a New Phase-Appropriate Manufacturing Model

Jesse McCool, Ph.D.

GBI Biomanufacturing

Data-Driven Mfg

Data-Driven Manufacturing and Digital Twins Across the Biologics Network

Jihyeon Oh; Hongwoo Joo

Samsung Biologics

CLD

Can Mammalian Cell-Line Engineering Become a High-Throughput Design Problem?

Pharma's Almanac

Bioprocessing

Bioprocessing and Capacity Trends: Growth Despite Continued Uncertainty

Cynthia A. Challener, Ph.D.

Pharma's Almanac

DS + DP Integration

Integrating Drug Substance and Drug Product to Reduce Risk Across Development

Dörthe Ackenhausen

IDT Biologika

Multi-Modality CDMO

The Rise of the Multi-Modality CDMO: Why Clients Need More Than Capacity

Kamal Preet

OneSource Specialty Pharma

DSP

Why More Product Upstream Creates New Pressure Downstream

Pharma's Almanac

BsAbs in Oncology

Bispecific Antibodies Move Into the Heme-Onc Mainstream

David Alvaro, Ph.D.

Pharma's Almanac